Divi's Labs targets double-digit growth with new peptide capacity
Management is betting on GLP-1 fragments and contrast media to drive revenue as it pushes ahead with a ₹1,500 crore expansion at Kakinada.
What's new
- Management projects double-digit revenue growth for the coming fiscal year.
- The company has validated several GLP-1 peptide fragments for commercial production.
- Iodine-based contrast media products are moving into commercial scaling for global innovators.
Why this matters
The shift toward complex segments like peptides and contrast media is the company's primary defense against generic pricing pressure. Successfully scaling these products is the only way to justify the ₹1,500 crore investment at Kakinada.
What we're watching
- The timeline for commercializing GLP-1 fragments.
- Impact of West Asian logistical disruptions on freight margins.
- Execution speed of the Kakinada site expansion.
The full read
Divi's Laboratories is leaning into high-value pharmaceutical segments to sustain growth. Management confirmed in its Q4FY26 earnings transcript that it expects double-digit revenue expansion in the coming fiscal year.
It is a pivot.
The strategy hinges on two pillars: commercializing iodine-based contrast media and scaling peptide manufacturing. The company has already validated several GLP-1 fragments, a critical milestone for entering the high-demand peptide market. To support this, the company is pouring ₹1,500 crore into its Kakinada site to clear space for new product launches. While management acknowledges rising freight costs and logistical friction in West Asia, the guidance remains firm. The next test is how quickly these validated peptide fragments move from the lab to global commercial supply chains, given the competitive landscape for GLP-1 therapeutics.
Questions answered
- What is the primary growth driver for Divi's Labs?
- Management is focusing on high-value segments, specifically peptide manufacturing and iodine-based contrast media. These areas are intended to support double-digit revenue growth.
- How is the company handling current logistical challenges?
- The company is managing increased freight costs and disruptions in West Asia. Despite these headwinds, management maintains its double-digit growth guidance.
- What is the status of the Kakinada project?
- The ₹1,500 crore expansion is underway. It is designed to create manufacturing space for upcoming high-value product launches.
- What progress has been made in peptide manufacturing?
- The company has completed the validation of several GLP-1 fragments. This is a key step in their strategy to enter the high-growth peptide market.